Calendar

Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. These health disparities result in avoidable readmissions, reduced quality of care, higher costs, and lower member satisfaction rates. Health care providers, insurers, and managed care pharmacy stakeholders need to identify organizational and system-based solutions to address systemic racial health disparities, including training Pharmacy & Therapeutics (P&T) committees properly on racial health equity, gaining a better understanding of best practices that can decrease racial health disparities related to benefit design, and disseminating these best practices.

This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.

The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. Forum participants will outline key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system.

This event is invitation only. If you're interested in participating, please email corpopportunities@amcp.org.

Drug development is expensive, time consuming, and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies must design drug development programs and clinical trials that meet FDA requirements. Especially with drugs approved via expedited pathways, the payers’ perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Forum participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products.

This event is invitation-only. If you're interested in participating, please email corpopportunities@amcp.org.